Chirfi Guindo

Five of the six sales of Chirfi Guindo are recent: they fall in the last twelve months, at Merck & Co., Inc., where the listed title is Chief Marketing Officer. The largest are EUR 2,065,540 on February 5, 2026, EUR 1,699,725 on August 6, 2026 and EUR 1,170,585 on August 13, 2026. In all, 6 sales represent EUR 8,073,761, with a median of EUR 1,142,255. No purchase is recorded.

The 32 filings, published from December 5, 2017 to August 13, 2026, are split between Biogen Inc. (20, EVP Glob. Prod Strat and Comm) and Merck & Co., Inc. (12). They include 14 grants and 12 option exercises. The year 2026 already gathers 8, against 1 to 5 a year before. The publication delay is a median of 2 days.

5, 3 and 3 trades by Guindo fall within 30 days of colleagues at Merck & Co., Inc., in that order. All on the same side. Colleagues in order: Richard R. DeLuca, Dean Y. Li and Johannes Jacobus Oosthuizen.